No Data
Onlikon: 2024 Annual Report
Onlikon: 2024 Annual Report Summary
Zhejiang Anglikang Pharmaceutical (002940.SZ): Received government subsidies totaling 24.2402 million yuan.
According to Gelonghui on April 14, Zhejiang Anglikang Pharmaceutical (002940.SZ) announced that the company and its subsidiaries are expected to receive a total of 24.2402 million yuan in various government subsidies from January 1, 2025, to April 11, 2025, of which 22.6283 million yuan is related to revenue and 1.6119 million yuan is related to assets.
Zhejiang Anglikang Pharmaceutical (002940.SZ): Received the approval notification for the listing application of the Chemical Raw Materials Active Pharmaceutical Ingredient Cephalexin (enzyme method process).
On April 10, Glonghui reported that Zhejiang Anglikang Pharmaceutical Co., Ltd. recently received the "Approval Notification for the Market Application of Active Pharmaceutical Ingredient Cefradine" issued by the National Medical Products Administration. Cefradine is a cephalosporin antibiotic. It is used to treat respiratory infections caused by sensitive bacteria, such as acute pharyngitis, tonsillitis, otitis media, bronchitis, and pneumonia, as well as infections of the genitourinary tract and skin soft tissue infections.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Zhejiang Anglikang Pharmaceutical (002940.SZ): The Business of pharmaceutical formulations does not include the production of Vitamins series formulations.
GL Honghui reported on March 17 that Zhejiang Anglikang Pharmaceutical (002940.SZ) stated on the investor interaction platform that the company's specialty intermediate Business includes a series of products such as plant-based Vitamins D3 and plant-based 25-hydroxy Vitamins D3; the company's Pharmaceutical formulation Business does not produce Vitamins series formulations.
The Market Doesn't Like What It Sees From Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s (SZSE:002940) Earnings Yet As Shares Tumble 28%
